Humacyte Stock Performance
| HUMA Stock | USD 2.53 0.14 5.24% |
Humacyte holds a performance score of 12 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.24, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Humacyte will likely underperform. Use Humacyte total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to analyze future returns on Humacyte.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Humacyte are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Humacyte sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.24) | Five Day Return 7.2 | Year To Date Return (51.16) | Ten Year Return (73.84) | All Time Return (73.84) |
1 | Humacyte Anticipates Q1 Earnings Announcement | 05/12/2025 |
2 | Is Humacyte A Risky Investment | 05/21/2025 |
3 | Acquisition by Sebelius Kathleen of 80000 shares of Humacyte at 2.41 subject to Rule 16b-3 | 06/12/2025 |
4 | Humacyte, Inc. Stock Declines While Market Improves Some Information for Investors | 06/30/2025 |
5 | Humacyte announces Symvess ECAT Approval from U.S. Defense Logi | 07/08/2025 |
6 | Humacyte Receives Steady Buy Rating from D. Boral Capital HUMA Stock News | 07/09/2025 |
7 | How does the FDA approval of Symvess impact Humacytes stock price - AInvest | 07/14/2025 |
8 | Humacyte, Inc. Dips More Than Broader Market What You Should Know | 07/18/2025 |
9 | What drives Humacyte Inc. Equity Warrant stock price - Free Stock Selection - Autocar Professional | 07/21/2025 |
10 | Humacyte rises on Symvess sale to military treatment facility | 07/23/2025 |
11 | Humacyte, Inc. Stock Dips While Market Gains Key Facts | 07/25/2025 |
| Begin Period Cash Flow | 80.8 M | |
| Total Cashflows From Investing Activities | -1.6 M | |
| Free Cash Flow | -99.7 M |
Humacyte Relative Risk vs. Return Landscape
If you would invest 146.00 in Humacyte on April 27, 2025 and sell it today you would earn a total of 107.00 from holding Humacyte or generate 73.29% return on investment over 90 days. Humacyte is currently generating 1.0944% in daily expected returns and assumes 6.9695% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Humacyte, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Humacyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Humacyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Humacyte, and traders can use it to determine the average amount a Humacyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.157
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HUMA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.97 actual daily | 62 62% of assets are less volatile |
Expected Return
| 1.09 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Humacyte is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Humacyte by adding it to a well-diversified portfolio.
Humacyte Fundamentals Growth
Humacyte Stock prices reflect investors' perceptions of the future prospects and financial health of Humacyte, and Humacyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Humacyte Stock performance.
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | (44.84) % | ||||
| Current Valuation | 345.45 M | ||||
| Shares Outstanding | 155.12 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 10.89 X | ||||
| Price To Sales | 759.09 X | ||||
| Gross Profit | (82.38 M) | ||||
| EBITDA | (132.23 M) | ||||
| Net Income | (148.7 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 16.54 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | 0.23 X | ||||
| Cash Flow From Operations | (98.12 M) | ||||
| Earnings Per Share | (0.69) X | ||||
| Market Capitalization | 392.45 M | ||||
| Total Asset | 137.87 M | ||||
| Retained Earnings | (686.01 M) | ||||
| Working Capital | 27.91 M | ||||
About Humacyte Performance
By analyzing Humacyte's fundamental ratios, stakeholders can gain valuable insights into Humacyte's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Humacyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Humacyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.23) | (1.30) | |
| Return On Tangible Assets | (1.08) | (1.02) | |
| Return On Capital Employed | (0.97) | (1.02) | |
| Return On Assets | (1.08) | (1.02) | |
| Return On Equity | 2.82 | 2.96 |
Things to note about Humacyte performance evaluation
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Humacyte is way too risky over 90 days horizon | |
| Humacyte appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (148.7 M) with loss before overhead, payroll, taxes, and interest of (82.38 M). | |
| Humacyte currently holds about 189.04 M in cash with (98.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Humacyte, Inc. Stock Dips While Market Gains Key Facts |
- Analyzing Humacyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Humacyte's stock is overvalued or undervalued compared to its peers.
- Examining Humacyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Humacyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Humacyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Humacyte's stock. These opinions can provide insight into Humacyte's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |